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INTRODUCTION TO PARKINSON’S DISEASE
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, after Alzheimer’s disease. Preva-
lence in people older than age 60 is approximately 1.4%.[1, 2] PD is characterized by many motor and non-motor symp-
toms. It presents with a range of motor symptoms usually consisting of asymmetric bradykinesia, resting tremor, and 
rigidity; postural instability may develop later in the course of the disease.[3, 4] However 'pre-motor' PD-a range of non-
motor symptoms, particularly sleep disorders, mood disorders, impaired sense of smell, and constipation may occur up 
to 20 years before the onset of motor symptoms.[5] The clinical paradigm has shifted from PD being considered a pure 
motor or movement disorder to being recognized as a systemic synucleinopathy with many motor and non-motor symp-
toms and signs. The etiology of PD is largely unknown, but a combination of genetic and environmental factors is postu-
lated. Several genes have been associated with inherited and early onset form of PD (LRK1, PINK1, Parkin, and DJ-1) 
but these represent only a small subset (10-15%) of all PD cases.[6] It is now known that PD can present with changes 
in mood, sleep, behavior, cognition and autonomic function this can initiate referrals to psychiatric, general medicine, 
geriatric, orthopedic and even rheumatology clinics, before neurological referral is considered. Etiology is multifactorial 
and is thought to be related to multiple mechanisms. Factors associated with development or Parkinsonism include expo-
sure to oxidant toxins (e.g. pesticides, MPTP), head trauma, manganese exposure, head trauma.
General Approach to Parkinson’s disease
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NATIONAL GUIDELINES FOR DIAGNOSIS AND
MANAGEMENT OF PARKINSON’S DISEASE IN PAKISTAN
Diagnosis of Parkinson’s disease 
The diagnosis of PD remains primarily clinical. In 1988, 
Gibb and Lees developed the Queen Square Brain Bank 
(QSBB) criteria for PD, based on careful clinical observa-
tion combined with clinicopathological correlation. In 
subsequent studies it has been demonstrated to have up 
to 90 % accuracy in diagnosing PD when diagnosed by 
an experienced neurologist. This is a three step recom-
mended strategy for diagnosis of Parkinson’s disease.
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UK Queen Square Brain Bank Criteria for the diag-
nosis of Parkinson's disease[7]
Step 1: Diagnosis of a Parkinsonian Syndrome
Bradykinesia (slow to initiate voluntary movement with 
progressively reduced speed and amplitude of  repetitive 
actions) and at least one of the following:
• Muscular rigidity
• Postural instability unrelated to primary visual, 
 cerebellar, vestibular or proprioceptive dysfunction
• Resting tremor
Step 2: Exclusion Criteria for Parkinson's Disease
History of:
• Repeated strokes with stepwise progression
• Repeated head injury
• Antipsychotics or dopamine-depleting drugs
• Definite encephalitis and/or oculogyric crisis on no 
 drug treatment
• More than one affected relative (Note: this exclusion 
 criteria is usually ignored)
• Sustained Remission 
• Negative response to large doses of levodopa (if 
 malabsorption excluded)
• Strictly unilateral features after 3 years
• Other neurological features: supranuclear gaze
 palsy, cerebellar signs, early severe autonomic 
 involvement, Babinski's sign, early severe dementia 
 with disturbance of language, memory or praxis 
• Exposure to Neurotoxin 
• Presence of cerebral tumour or communicating 
 hydrocephalus on neuroimaging
Step 3: Supportive Criteria for Parkinson's Disease
Three or more of the following are required for the 
diagnosis of definite Parkinson's disease 
• Unilateral onset
• Rest tremor present
• Progressive disorder
• Persistent asymmetry primarily affecting the side
 of initial onset
• Excellent response to levodopa (70%–100%)
• Severe levodopa-induced chorea
• Levodopa response for more than 5 years
• Clinical course of over 10 years
Work up of Parkinsonism at Initial Presentation
In patients with a clear clinical diagnosis and no atypical 
signs the physician may decide not to order blood tests or 
neuroimaging studies. There is no definitive diagnostic 
test for PD. These tests are performed to diagnose other 
conditions that may present like Parkinson’s disease. 
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[9-11]
Parkinson’s disease Mimics
 
Once structural, infectious, toxic and metabolic causes of Parkinsonism have been excluded, the evaluating physician 
must consider features of the patient’s history and physical examination that may suggest an alternative cause for the 
symptoms. A diagnosis of idiopathic PD should be assumed only after ruling out PD mimics such as other tremor disor-
ders, drug-induced Parkinsonism, vascular parkinsonism, normal pressure hydrocephalus and parkinsonism-plus condi-
tions. The following table outlines features that may help in the differential diagnosis of these conditions:[3]
Parkinson’s disease more likely
Slow onset and progression of symptoms over months 
and years
For example a 55 year old man presenting with slowly 
progressive difficulty using left hand with a mild tremor 
at rest over the past year
Unilateral disease or significant asymmetry on signs 
and symptoms in the beginning of the disease
Tremor:
Tremor usually involves extremities and, less commonly 
the jaw. Head tremor is almost never present in 
idiopathic PD. 25% of Parkinson’s patients may never 
manifest a tremor. The classic tremor in Parkinson’s 
disease is a slow resting (low frequency) pill-rolling 
tremor best seen when the hands are at rest or while 
the patient is walking.It decreases with activity and can 
be suppressed temporarily by the patient. Re-emergent 
tremor: Tremor tends to diminish at least temporarily 
once the patient is asked to stretch out the arms and 
may return as this becomes the new rest position. 
Onset of tremor is generally unilateral and over time 
may involve the other side
Responsive to Levodopa
Autonomic symptoms include urinary urgency, orthostasis
Bulbar involvement is possible 
Falls occur late after significant rigidity or bradykinesia 
develop
Non motor symptoms may include constipation, anosmia, 
insomnia and depression.
Lack of eye movement restriction except there may be some  
impairment of conjugate upgaze and convergence
Lack of early respiratory muscle compromise
    
Alternative diagnosis more likely
Sudden onset or rapid progression over days and weeks 
should suggest an alternative diagnosis such as a 
stroke, brain tumour or TB meningitis
Symmetrical onset more commonly is associated with other 
Parkinsoniansyndromes such as Diffuse Lewy Body disease, 
Multisystem Atrophy, Progressive Supranuclear Palsy etc. 
Tremor:
Enhanced physiologic tremor: Tremor related to anxiety 
is present in outstretched hands and throughout the 
range of motion. Benign essential tremor is more 
prominent when the patient stretches out his hands as 
it is predominantly a postural tremor. Benign essential 
tremor often involves the head causing a side-to-side or 
up/down tremor (a 'no-no' or ‘yes-yes’ tremor). ). It can 
affect the voice, is worsened with activity and is often 
familial. Parkinson’s plus syndromes are less likely to 
have a tremor at presentation.
Lack of robust response to Levodopa
Early onset of multiple autonomic symptoms suggest 
MSA
Predominant early bulbar signs suggest a Parkinson’s 
Plus syndrome like PSP 
Frequent falls early in the course of disease suggests  a 
Parkinson’s Plus syndrome like PSP 
Vertical gaze palsy in which initial abnormality is impair-
ment of downgaze with intact oculocephalic maneuver 
suggests PSP 
Stridor/strangulated dysarthria suggests MSA
Chronic history of neuroleptic use or antiemetic use 
suggests a medication induced parkinsonism 
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Table 1
Neuroimaging in Parkinson’s disease and Parkinson’s Plus Syndromes
In a patient with classic features of Parkinson’s disease, 
and absence of red flags for atypical Parkinsonism, 
neuroimaging is not indicated initially. If the patient 
subsequently develops any atypical features, then brain 
MRI without contrast can be considered [10, 12] Treatment 
of Motor Symptoms in Parkinson’s disease PD is the 
only common neurodegenerative condition in which 
effective long-term treatment is readily available.  Spe-
cial care needs to be exercised in treating PD as both 
under treatment and over treatment can worsen a 
patient's condition and may even accelerate the 
progression to disability. The key is to treat the patient 
appropriately and not to under or over treat. This implies 
a level of treatment that relieves symptoms to the point 
that the patient has a fairly good quality of life. The 
physician needs to explain to the patient early on that 
PD is an incurable but treatable disease that will require 
a lifelong patient-physician partnership. The objectives 
of optimal treatment should be clearly explained. The 
objectives should be to treatment to a point that the 
patient is adequately functional and has a good quality 
of life. The first step in managing PD is to determine 
whether treatment is needed or not. It is important for 
the physician to partner with the patient and the family 
to treat PD. The treatment usually results in many years 
of a productive and functional life. In many patients the 
disease does progress and the symptoms become 
refractory to the treatments. Patients with social or 
functional impairment should be initiated on treatment 
and almost all patients that present to a physician 
require some form of treatment. The most obvious 
motor symptom for many patients is tremor, which is 
socially distressing; however the tremor often does not 
impair function if it is not severe. Rigidity, bradykinesia 
and in later stages postural instability are frequently 
greater sources of functional impairment. [30] The first 
step in managing a diagnosed case of PD is to deter-
mine whether treatment is needed or not. It is impor-
tant for the physician to partner with the patient and the 
family to treat PD. It is important that the patient under-
stands that the treatment will allow for many years of 
very adequate function but that the disease is progres-
sive and incurable. Any patient with social or functional 
impairment should be initiated on treatment. Almost all 
patients that present to a physician require some form 
of treatment. The most obvious motor symptom for 
many patients is tremor, which is socially distressing; 
however the tremor often does not impair function if it 
is not severe. Rigidity, bradykinesia and in later stages 
postural instability are frequently greater sources of 
functional impairment. [13]
Overview of Pharmacologic Therapy for Motor 
Symptoms in Parkinson’s disease [9, 13-17]
Pharmacologic treatment options include: Carbidopa/ 
levodopa; sooner or later virtually all patients with PD 
will require carbidopa/levodopa. Dopamine agonists 
(although not as effective ascarbidopa/ levodopa, carry 
an advantage of delaying motor fluctuations and dyski-
nesias, especially in younger patients) [35]. Monoamine 
oxidase type B inhibitors (symptomatic improvement is 
modest with these); these are rasagiline and 
selegiline)[36]. Anticholinergics (eg procyclidine and 
trihexyphenidyl). These predominantly improve the 
tremor, drooling and urinary frequency. These are asso-
ciated with many adverse effects, which may be 
particularly severe in the elderly and include urinary 
retention, constipation, blurred vision, dry mouth, 
confusion, and orthostatic hypotension)[34,37]. Amanta-
dine [38] may reduce dyskinesias very effectively and can 
also help tremor and fatigue. COMT inhibitors 
(entacapone, tolcapone)[39]; prolong the half-life of 
carbidopa/levodopa and make it last longer and make it 
more effective.
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Carbidopa/ levodop
A variety of pharmacologic and non-pharmacologic 
treatments are effective in treating PD. The cheapest 
and the most effective medication is still 
carbidopa/levodopa. Common adverse effects include 
nausea and light headedness. In the past there was 
concern about potential neurotoxicity and acceleration 
of underlying disease associated with use of 
carbidopa/levodopa but this concern has been laid to 
rest. Recent studies reveal earlier use of 
carbidopa/levodopa does not  accelerate progression of 
PD. Peak-dose dyskinesia (involuntary-dance like move-
ments) may develop after several years of using 
carbidopa/levodopa in younger patients and patients on 
high doses. This is one reason why many neurologists 
would prefer to avoid carbidopa/levodopa as first line 
treatment in the younger (<60 years age) patient and 
initiate treatment with a dopamine agonist and rasagil-
ine instead. In individuals already on carbidopa/ 
levodopa, shortening the interdose interval and reduc-
ing individual doses may reduce the severity and even 
postpone development of motor fluctuations and 
complications [40]. In Pakistan the available formulation 
of levodopa contains 250 mg levodopa in combination 
with 25 mg of carbidopa. This may not be the optimal 
formulation to be given in the earlier stages of PD. 
Using a 25 carbidopa/100 levodopa formulation 
(available as imported medicine) or quarter or half of 
the 25/250 pill may be better.
Dopamine Agonists
Dihydroergocryptine, pergolide, pramipexole, ropinirole, 
piribedil, rotigotine, bromocriptine, cabergoline and 
lisuride are the dopamine agonists used in PD.  Ropin-
irole is the most widely available and frequently used 
dopamine agonist in Pakistan. There is no particular 
difference in efficacy between different dopamine 
agonists, so physicians should familiarize themselves 
with the dosage titration and potential adverse effect of 
one of them. Ergot-based dopamine agonists, such as 
bromocriptine, are still used in Pakistan but should be 
avoided due to the associated high frequency of cardiac 
valvular, peritoneal and pleural fibrosis. Common 
adverse effects of dopamine agonists include: Sedation 
(may be severe and cause sleep attacks that may be 
sudden and severe enough to cause car accidents). 
Confusion, disorientation, hallucinations, delusions, 
psychosis and hallucinations. Postural hypotension and 
nausea. Impulse control disorder; this can consist of 
pathological gambling, hypersexuality, compulsive 
eating, compulsive shopping, compulsive hobbying. 
Response to Treatment as Parkinson’s disease 
Progresses
As PD progresses the response to treatment varies. 
Early Parkinson's disease; The early stage of  PD is also 
called the “honeymoon period” when symptoms 
respond well to a variety of treatments and there is a 
sustained response to single doses of medications. [41]
Late Parkinson's disease; As PD progresses, the 
response to dopamine therapy becomes less sustained, 
probably as a consequence of the loss of dopaminergic 
neurons. Motor fluctuations develop and the addition of 
MAO-B inhibitors or COMT-inhibitors may then be 
considered. These agents increase the potency of 
levodopa and prolong its effect by inhibiting the meta-
bolic breakdown of levodopa and increasing its 
bio-availability. If given in combination with Carbidopa/ 
levodopa they help to decrease off-time and prolong the 
on-time. MAO-B inhibitors include selegiline and 
rasagiline. This class of drug produces modest sympto-
matic benefit but has not been shown to delay motor 
complications. A rare adverse effect of selegiline but 
not rasagiline is precipitation of a hypertensive crisis if 
consumed with tyramine containing foods. COMT-
inhibitors includeentacapone and tolcapone. COMT- 
inhibitors produce moderate improvement in motor 
symptoms. Entacapone in combination with levodopa 
shows minimal delay in onset of motor complications 
(dyskinesia). Tolcapone comes with a black box warning 
for fulminant liver failure, which may be fatal.
Treatment of Parkinson’s disease based on Patient’s Age 
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In patients older than 60 years of age who present with 
symptoms, consider starting with carbidopa/levodopa 
as it is more effective and generally better tolerated. In 
younger patients (<60 years) it may be better to start 
with one of the dopamine agonists in order to delay the 
dyskinesias that may occur with Carbidopa/levodopa 
therapy, particularly in the young PD patients. Eventu-
ally even the younger patients may require Carbidopa/ 
levodopa as the disease progresses and a more potent 
medication is needed. 
Drug Class                 Indication                                                                          Impact on Motor symptoms                               Important Adverse Effects
Levodopa                   First line therapy in patients over 60 years of age                      Excellent                                                              Motor fluctuations Dyskinesia
Dopamine Agonists     First line therapy in younger patients                                       Moderate                                                             Sedation/sleep attacks
                                or add on to carbidopa/levodopa                                                                                                                        Impulse control disorder
                                                                                                                                                                                                      Pedal edema, Weight gain
MAO-B Inhibitors        First line for mild disease with depression.                               Limited                                                                Serotonin syndrome and  
                                Add on therapy for motor fluctuationsto carbidopa/levodopa                                                                                  hypertensive crises may rarely occur
                                                                                                                                                                                                      Narrow therapeutic window 
COMT inhibitors          Add on therapy for motor fluctuations                                      Improves wearing off of Carbidopa/levodopa             Diarrhea 
Anticholinergics          Limited use. Only improves PD tremor                                      Limited                                                                Confusion, Dry eyes/mouth 
                                                                                                                                                                                                      Urinary retention, Constipation 
Amantadine               Reduces dyskinesias and can improve                                     Limited                                                                Confusion 
                                 wearing off symptoms                                                                                                                                      Lividoreticularis
                                                                                                                                                                                                      Pedal edema
Table 2 [3]
Relative Efficacy Profile
Factors affecting treatment choices        Levodopa     Dopamine Agonists     MAO-B Inhibitors    COMT Inhibitors 
Efficacy on motor symptoms                High            Moderate                 Low                     Moderate
Ease of Use                                        Low             Moderate                 Moderate             Low- Moderate 
Risk of inducing motor complications     High            Low                         Low                     Low 
Table 3 Relative Cost of Different Medications (as listed in Pharma guide 2014, electronic version)
Table 4
Titration Template for Commonly Used Medications for Motor Symptoms in Parkinson’s disease [19, 20]
Medication                           Start of titration      Weekly up-titration           Maintenance dose        Daily dose 
Carbidopa/levodopa                 50 mg AM                50 mg Q3day                    3-4 x 100 mg                  300-800 mg
Pramipexole                            3x0.088 mg              2nd week 3x0.18mg
                                                                           3rd week 3x0.35mg
                                                                           Then weekly 3x0.18 mg      3x0.35-0.7 mg                1.05-3.3 mg
Pramipexole ER                      0.25 mg AM             2nd week 0.52 mg             1x 1.05-2.1 mg              1.05-3.15 mg
                                                                           3rd week 1.05 mg
                                                                           4th week 2.1 mg
                                                                           5th week 3.15 mg 
Ropinirole                               1 mg AM                  Weekly 1mg                      3x 3-8 mg                      6-24 mg 
Ropinirole ER                          2 mg AM                  2 mg                                6-24 mg                         6-24 mg 
Rotigotine Patch                     2mg/24h                  2mg/24 hr                         4-8 mg/24h                    8-16 mg/24h
Piribedil                                  50 mg HS                 50 mg every 2 weeks         2-3 x 50 mg                   150-250 mg 
Selegiline                                                                                                      5-10 mg                         5-10 mg 
Rasagiline                                                                                                      1 mg                              1 mg 
Entacapone                            50 mg AM                50 mg every 3 days            3-4 x 100 mg                 600 mg 
Tolcapone                               100 mg AM                                                      2-3 x 100 mg                 600 mg 
                                                                                                                   at 6-12 hour intervals 
Amantadine                           100 mg AM              100 mg q3days                 1-3 x 100 mg                 100-400 mg
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Table 1; Characteristics of commonly used medications for motor symptoms in PD [19]
Carbidopa/        Name of company    Price in PKR /tablet      Rasagiline 1 mg           Name of company     Price in PKR /tablet      Ropinirole      Name of       Price in
levodopa                                                                                                                                                                                   1 mg            company       PKR/tablet
25/250 mg                                                                                                                                                                                                                          
Aptidopa            aptcure                      8                                 Alzilo                             Searle                         19.20                            Propinol          Shrooq           9.50
Dopasel             kurative                     8                                 Rasagin                         HiranisPharma             11.40                            Reol               Genome         16,66
Meddopa           medera                      8                                                                                                                                          Requip            GSK               34.28
Neudopa           Platinum                    8                                 Amantadine 100 mg       Name of company        Price in PKR /tablet          Ronirol            Hilton             21.19
Sinedopa           Valor/Al-Hameed         9                                 Amantin                        Gene-Tech                   11.35                            Ropinol           Amarant         24,33
Sinemet            OBS                          14.61                          PK-Merz                        Brookes                      15.60                            XMG               Atco               12
                                                                                          Viofral                           Biocare                       13.25
Deep Brain Stimulation in Parkinson’s disease [21] 
Deep brain stimulation of the sub thalamic nucleus or 
globus pallidus internum is used in the treatment of motor 
symptoms of PD. There are multiple theories to suggest 
the mechanism of action including a micro-lesioning 
effect, resetting of aberrant pathways and circuits and 
modulating excito-toxicity.
Deep brain stimulation of the subthalamic nucleus or globus 
pallidum may be considered in the following situations.
• Medication refractory disabling tremor.
• Carbidopa/Levodopa responsive disease.
• Motor fluctuations (on-off fluctuating motor symptoms
 that require high doses of medications that need to be
 given very frequently.
• Disabling dyskinesias.
• Patient does not have dementia or severe depression.
Axial and autonomic symptoms and freezing of the gait 
usually does not get better with this surgery. The surgery 
should only be done by high trained and experienced 
Parkinson’s disease surgeons and after the surgery the 
medications and the stimulator needs to be adjusted by 
experienced Parkinson’s disease neurologists. It requires 
life-long management by these teams and if not done and 
managed properly can often make the condition of the 
patient worse after the surgery.
Treatment of Non-Motor Symptoms in
Parkinson’s Disease
Non-motor symptoms are a major contributor to impaired 
quality of life of patients suffering from PD. [5] However, 
these symptoms are often neglected during evaluation 
and treatment. Non-motor symptoms are often easily 
treatable, but lack of attention to them may make treat-
ment of motor symptoms more difficult.[12] Non-motor 
symptoms include behavioral symptoms like depression, 
anxiety and psychosis, sleep disorders, dementia, dysau-
tonomia (dysphagia, drooling, constipation, urinary 
urgency and frequency, orthostatic hypotension) and 
sensory symptoms (pain, Restless Legs Syndrome, numb-
ness, joint stiffness in the limbs affected by the symp-
toms, etc). Non-motor symptoms can precede motor 
symptoms by years.
Sleep Disorders:
These include rapid eye movement (REM) sleep behavi or 
disorder (acting out dreams), insomnia, restless legs 
syndrome (RLS), and poor sleep maintenance. Usually 
the history provides the diagnostic clues needed to 
address sleep issues. Insomnia can be related to lack of 
dopamine or underlying anxiety/ depression. Nocturia 
may disturb the normal sleep pattern and may be due 
to an over active bladder or an underlying sub-clinical 
urinary tract infection.. Dopaminergic drug-wearing-off 
may contribute to poor sleep and this may require a 
bedtime dose of a long acting dopaminergic agent. 
Restless legs syndrome is commonly associated with 
Parkinson's disease and can be readily diagnosed and 
treated. RLS presents with restlessness, pain, cramps 
or vague discomfort in the legs upon rest, particularly 
after laying down to sleep at night. The symptoms 
improve upon movement, such as moving the legs or 
getting up and walking, but symptoms often return once 
the patient is recumbent again. RLS is associated with 
involuntary leg movements as well, which can occur 
during wakefulness or sleep. RLS symptoms should 
trigger a search for underlying iron deficiency, which 
should then be treated with iron replacement and 
Vitamin C which may facilitate its absorption. If iron 
deficiency is not present, RLS responds well to dopa-
minergic agonists such as ropinirole, typically adminis-
tered 2 hours before bedtime. Gabapentin, pregabalin 
and tramadol also are effective REM sleep behavior 
disorder includes a variety of presentations wherein 
patients may seem to be acting out dreams. Questioning 
the family members may reveal the patient has been 
talking in their sleep or even thrashing around and 
acting out physical fights while asleep (which may result 
in injuries). Always screen for REM sleep behavior disorder 
as it is a treatable condition.[22-25] It is usually responsive 
to a low dose of clonazepam.
Depression And Anxiety:
Mood disorders are common in Parkinson's disease and 
are frequently under-recognized and under-treated. PD 
patients with depression may be difficult to motivate to 
engage in regular exercise and in rehabilitation 
programs.  They also are more likely to be noncompliant 
with treatment. Serotonin specific reuptake inhibitors 
(SSRI's) often are effective in usual doses and can 
greatly improve the quality of life of the patients. 
Episodic shortness of breath and sweating are often 
seen with advancing Parkinson's disease and may or 
may not respond to dopaminergic medication. These 
resemble panic attacks.[17,18]. Anxiety can be a non-
motor component of PD and although it perhaps most 
often appears as a wearing off phenomenon, it also can 
present as a more pervasive sense of anxiety in some 
patients. It can often be treated by giving the dopaminergic 
medications more frequently at lower doses. 
Dementia:
PD dementia may develop in people after several years 
and correlates with the presence of subcortical and 
cortical Lewy bodies. Environmental modifications are 
the best tolerated interventions. Try to minimize 
changes to routine, provide familiar things and memory 
cues to minimize agitation. 
Discontinue potential aggravators: 
Anticholinergics, amantadine, tricyclic antidepressants, 
tolterodine and oxybutynin, benzodiazepines. If treatment 
becomes necessary, the addition of a cholinesterase 
inhibitor, such as rivastigmine, donepezil or galantamine 
may be considered. Memantine also may be tried.[26, 27]
Psychosis:
Symptoms of psychosis, such as hallucinations, 
delusions, and illusions, are complications of therapy 
and also may arise from the progression of the disease 
process. When they occur, it is important to first correct 
any metabolic abnormalities or fluid imbalance and to 
treat any infection. It is important to minimize poly-
pharmacy. Decreasing or stopping non-levodopa medi-
cations and optimizing levodopa can improve psychosis. 
Antipsychotics may be needed, but those that are 
potent dopamine depleting drugs can worsen Parkin-
sonism, especially the typical antipsychotics. Quetia-
pine is a sedating antipsychotic that does not appear to 
worsen the motor symptoms of Parkinson's disease.  
However as with other atypical antipsychotics, there 
may be a small risk of cardiac complications and therefore 
its use requires considering the risks and benefits for 
each individual patient.
 
Urinary Urgency, Frequency and Nocturia:
These are common autonomic symptoms in PD. Recog-
nizing and treating sub-clinical urinary tract infection is 
very important. Initial treatment may involve reduced 
intake of fluids after 6 pm and no caffeinated drinks 
after 12 noon. If that is not sufficient, then anticholiner-
gic medications may help. Anticholinergics that do not 
cross the blood brain barrier are better, since these do 
not worsen cognition. Tolterodine (2 mg twice daily) can 
be considered for these symptoms. Botulinum toxin 
type A injected in the detrusor muscle can also help but 
is a very expensive form of treatment that should be 
given only by trained physicians.[22,23]. For patients who 
cannot tolerate medications, diapers and bedside 
urinals should be available for patients.
Dysphagia:
Multiple factors contribute to dysphagia in PD. Optimization 
of motor control with dopamine replacement therapy 
may be helpful. Speech therapy is important along with 
assessment of swallowing and advice regarding the 
prevention of aspiration. Enteral feeding options 
(short-term nasogastric tube or percutaneous endo-
scopic gastrostomy) may be needed in advanced cases. 
[24]. Eating pureed and soft foods with the head slightly 
bent may be better and extra care with thin fluids like 
water and tough foods like meat that are more likely to 
cause dysphagia is important. Pills can be also be 
crushed and administered with yogurt to facilitate 
swallowing.
Orthostatic hypotension:
This is very important to recognize, prevent and treat as it 
can cause dizziness, fainting spells and falls. This is 
aggravated by volume depletion, diuretics, antihyperten-
sive drugs, tricyclic antidepressants, nitrates and alpha-
blockers used to treat prostatic hypertrophy. Dopaminer-
gic drugs also may induce orthostatic hypotension. It 
improves with increased salt intake.  Elevating the head-
end of the bed at night (30–40°) may be helpful, as may 
wearing of waist-high elastic-pressure stockings and/or 
abdominal binders (if weather allows). Changing positions 
slowly and exercises of the legs (leg crossing, toe raising, 
and thigh contraction) before sitting up and standing can 
help. If all of these are unsuccessful, medications, such 
as midodrine or fludrocortisone, may be necessary. [25,26]. 
Domperidone can block the peripheral effect of the dopa-
minergic medications and can help as well.
Constipation:
Constipation is a manifestation of general bradykinesia 
and autonomic dysfunction in Parkinson’s disease. This 
is a common problem aggravated by poor oral intake of 
water/fiber. Bowel dysfunction has two components 
decreased bowel movement frequency and difficulty 
with the act of defecation. Decreased bowel movement 
frequency results from slow colon transit and the 
difficulty with the act of defecation is due to impaired 
coordination and relaxation of the anorectal muscles.  
Slow transit constipation often responds to increasing 
water intake, fiber (ispaghula husk) and regular use of 
Milk of Magnesia or lactulose. Defecatory dysfunction 
usually does not respond to these interventions.
Drooling:
Drooling is another common and distressing symptom. 
Drooling is typically due to impairment of the swallowing 
mechanism rather than overproduction of saliva and 
may improve with chewing gum or sucking on honey or 
ice. Drooling may require use of anticholinergic agents 
or botulinum toxin injections into the salivary glands [19]. 
However anticholinergics should generally be avoided in 
the elderly patients and those with cognitive impairment 
as they can result in confusion, hallucinations, blurring 
of vision, constipation and urinary retention.
Pain and Dystonia:
Patients with PD suffer from pain related to multiple 
pathogenic mechanisms, including central and periph-
erally mediated pain. Some of this may be related to 
immobilization from bradykinesia or dystonia. Exercise, 
physical therapy, pain management and botulinum 
toxin injections for dystonia may improve the quality of 
life of the patient.[28-30] 
When to Refer to a Neurologist
Primary care providers can diagnose and treat Parkinsons 
however consider referring to a neurologist if diagnosis is not 
clear; difficulty in managing or complications with manage-
ment; suboptimal response with management options
Importance of Multidisciplinary Care in the 
Management of Parkinson’s disease
Effective management of PD not only includes management 
of motor and non-motor symptoms but also addressing 
multiple areas of rehabilitation and improving the quality of 
life of the individual as a whole. There is a significant role 
for speech therapy, swallow evaluations, physical 
therapy, exercise and gait training from the time of 
diagnosis. Counseling patients and discussing possible 
modifications to their life style and home set-up in 
anticipation of expected disease progressionalsoare 
important. There is increasing data to suggest that 
exercise is neuroprotective for Parkinson’s disease, may 
improve executive function and slow progression of 
motor symptoms. SPARX trial and other smaller studies 
show that exercise improves motor scores in patients 
with Parkinson’s disease hence reducing falls and 
improves quality of life.[31-44]  Levodopa therapy is related 
to increase homocystine due to its metabolism by COMT 
enzyme. This theoretically increases the risk of stroke in 
patients suffering from Parkinson’s treated with 
levodopa. It might be reasonable to treat prophylacti-
cally with Vitamin B 12, folate, Vitamin B6.[45] Rehabili-
tation measures are focused towards improving mobility 
and preventing fall-related morbidity. The team caring for 
a PD patient should ideally be a combination of a physi-
cian, speech therapist, occupational therapist and 
physical therapist.[13, 46, 47]
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Deep Brain Stimulation in Parkinson’s disease [21] 
Deep brain stimulation of the sub thalamic nucleus or 
globus pallidus internum is used in the treatment of motor 
symptoms of PD. There are multiple theories to suggest 
the mechanism of action including a micro-lesioning 
effect, resetting of aberrant pathways and circuits and 
modulating excito-toxicity.
Deep brain stimulation of the subthalamic nucleus or globus 
pallidum may be considered in the following situations.
• Medication refractory disabling tremor.
• Carbidopa/Levodopa responsive disease.
• Motor fluctuations (on-off fluctuating motor symptoms
 that require high doses of medications that need to be
 given very frequently.
• Disabling dyskinesias.
• Patient does not have dementia or severe depression.
Axial and autonomic symptoms and freezing of the gait 
usually does not get better with this surgery. The surgery 
should only be done by high trained and experienced 
Parkinson’s disease surgeons and after the surgery the 
medications and the stimulator needs to be adjusted by 
experienced Parkinson’s disease neurologists. It requires 
life-long management by these teams and if not done and 
managed properly can often make the condition of the 
patient worse after the surgery.
Treatment of Non-Motor Symptoms in
Parkinson’s Disease
Non-motor symptoms are a major contributor to impaired 
quality of life of patients suffering from PD. [5] However, 
these symptoms are often neglected during evaluation 
and treatment. Non-motor symptoms are often easily 
treatable, but lack of attention to them may make treat-
ment of motor symptoms more difficult.[12] Non-motor 
symptoms include behavioral symptoms like depression, 
anxiety and psychosis, sleep disorders, dementia, dysau-
tonomia (dysphagia, drooling, constipation, urinary 
urgency and frequency, orthostatic hypotension) and 
sensory symptoms (pain, Restless Legs Syndrome, numb-
ness, joint stiffness in the limbs affected by the symp-
toms, etc). Non-motor symptoms can precede motor 
symptoms by years.
Sleep Disorders:
These include rapid eye movement (REM) sleep behavi or 
disorder (acting out dreams), insomnia, restless legs 
syndrome (RLS), and poor sleep maintenance. Usually 
the history provides the diagnostic clues needed to 
address sleep issues. Insomnia can be related to lack of 
dopamine or underlying anxiety/ depression. Nocturia 
may disturb the normal sleep pattern and may be due 
to an over active bladder or an underlying sub-clinical 
urinary tract infection.. Dopaminergic drug-wearing-off 
may contribute to poor sleep and this may require a 
bedtime dose of a long acting dopaminergic agent. 
Restless legs syndrome is commonly associated with 
Parkinson's disease and can be readily diagnosed and 
treated. RLS presents with restlessness, pain, cramps 
or vague discomfort in the legs upon rest, particularly 
after laying down to sleep at night. The symptoms 
improve upon movement, such as moving the legs or 
getting up and walking, but symptoms often return once 
the patient is recumbent again. RLS is associated with 
involuntary leg movements as well, which can occur 
during wakefulness or sleep. RLS symptoms should 
trigger a search for underlying iron deficiency, which 
should then be treated with iron replacement and 
Vitamin C which may facilitate its absorption. If iron 
deficiency is not present, RLS responds well to dopa-
minergic agonists such as ropinirole, typically adminis-
tered 2 hours before bedtime. Gabapentin, pregabalin 
and tramadol also are effective REM sleep behavior 
disorder includes a variety of presentations wherein 
patients may seem to be acting out dreams. Questioning 
the family members may reveal the patient has been 
talking in their sleep or even thrashing around and 
acting out physical fights while asleep (which may result 
in injuries). Always screen for REM sleep behavior disorder 
as it is a treatable condition.[22-25] It is usually responsive 
to a low dose of clonazepam.
Depression And Anxiety:
Mood disorders are common in Parkinson's disease and 
are frequently under-recognized and under-treated. PD 
patients with depression may be difficult to motivate to 
engage in regular exercise and in rehabilitation 
programs.  They also are more likely to be noncompliant 
with treatment. Serotonin specific reuptake inhibitors 
(SSRI's) often are effective in usual doses and can 
greatly improve the quality of life of the patients. 
Episodic shortness of breath and sweating are often 
seen with advancing Parkinson's disease and may or 
may not respond to dopaminergic medication. These 
resemble panic attacks.[17,18]. Anxiety can be a non-
motor component of PD and although it perhaps most 
often appears as a wearing off phenomenon, it also can 
present as a more pervasive sense of anxiety in some 
patients. It can often be treated by giving the dopaminergic 
medications more frequently at lower doses. 
Dementia:
PD dementia may develop in people after several years 
and correlates with the presence of subcortical and 
cortical Lewy bodies. Environmental modifications are 
the best tolerated interventions. Try to minimize 
changes to routine, provide familiar things and memory 
cues to minimize agitation. 
Discontinue potential aggravators: 
Anticholinergics, amantadine, tricyclic antidepressants, 
tolterodine and oxybutynin, benzodiazepines. If treatment 
becomes necessary, the addition of a cholinesterase 
inhibitor, such as rivastigmine, donepezil or galantamine 
may be considered. Memantine also may be tried.[26, 27]
Psychosis:
Symptoms of psychosis, such as hallucinations, 
delusions, and illusions, are complications of therapy 
and also may arise from the progression of the disease 
process. When they occur, it is important to first correct 
any metabolic abnormalities or fluid imbalance and to 
treat any infection. It is important to minimize poly-
pharmacy. Decreasing or stopping non-levodopa medi-
cations and optimizing levodopa can improve psychosis. 
Antipsychotics may be needed, but those that are 
potent dopamine depleting drugs can worsen Parkin-
sonism, especially the typical antipsychotics. Quetia-
pine is a sedating antipsychotic that does not appear to 
worsen the motor symptoms of Parkinson's disease.  
However as with other atypical antipsychotics, there 
may be a small risk of cardiac complications and therefore 
its use requires considering the risks and benefits for 
each individual patient.
 
Urinary Urgency, Frequency and Nocturia:
These are common autonomic symptoms in PD. Recog-
nizing and treating sub-clinical urinary tract infection is 
very important. Initial treatment may involve reduced 
intake of fluids after 6 pm and no caffeinated drinks 
after 12 noon. If that is not sufficient, then anticholiner-
gic medications may help. Anticholinergics that do not 
cross the blood brain barrier are better, since these do 
not worsen cognition. Tolterodine (2 mg twice daily) can 
be considered for these symptoms. Botulinum toxin 
type A injected in the detrusor muscle can also help but 
is a very expensive form of treatment that should be 
given only by trained physicians.[22,23]. For patients who 
cannot tolerate medications, diapers and bedside 
urinals should be available for patients.
Dysphagia:
Multiple factors contribute to dysphagia in PD. Optimization 
of motor control with dopamine replacement therapy 
may be helpful. Speech therapy is important along with 
assessment of swallowing and advice regarding the 
prevention of aspiration. Enteral feeding options 
(short-term nasogastric tube or percutaneous endo-
scopic gastrostomy) may be needed in advanced cases. 
[24]. Eating pureed and soft foods with the head slightly 
bent may be better and extra care with thin fluids like 
water and tough foods like meat that are more likely to 
cause dysphagia is important. Pills can be also be 
crushed and administered with yogurt to facilitate 
swallowing.
Orthostatic hypotension:
This is very important to recognize, prevent and treat as it 
can cause dizziness, fainting spells and falls. This is 
aggravated by volume depletion, diuretics, antihyperten-
sive drugs, tricyclic antidepressants, nitrates and alpha-
blockers used to treat prostatic hypertrophy. Dopaminer-
gic drugs also may induce orthostatic hypotension. It 
improves with increased salt intake.  Elevating the head-
end of the bed at night (30–40°) may be helpful, as may 
wearing of waist-high elastic-pressure stockings and/or 
abdominal binders (if weather allows). Changing positions 
slowly and exercises of the legs (leg crossing, toe raising, 
and thigh contraction) before sitting up and standing can 
help. If all of these are unsuccessful, medications, such 
as midodrine or fludrocortisone, may be necessary. [25,26]. 
Domperidone can block the peripheral effect of the dopa-
minergic medications and can help as well.
Constipation:
Constipation is a manifestation of general bradykinesia 
and autonomic dysfunction in Parkinson’s disease. This 
is a common problem aggravated by poor oral intake of 
water/fiber. Bowel dysfunction has two components 
decreased bowel movement frequency and difficulty 
with the act of defecation. Decreased bowel movement 
frequency results from slow colon transit and the 
difficulty with the act of defecation is due to impaired 
coordination and relaxation of the anorectal muscles.  
Slow transit constipation often responds to increasing 
water intake, fiber (ispaghula husk) and regular use of 
Milk of Magnesia or lactulose. Defecatory dysfunction 
usually does not respond to these interventions.
Drooling:
Drooling is another common and distressing symptom. 
Drooling is typically due to impairment of the swallowing 
mechanism rather than overproduction of saliva and 
may improve with chewing gum or sucking on honey or 
ice. Drooling may require use of anticholinergic agents 
or botulinum toxin injections into the salivary glands [19]. 
However anticholinergics should generally be avoided in 
the elderly patients and those with cognitive impairment 
as they can result in confusion, hallucinations, blurring 
of vision, constipation and urinary retention.
Pain and Dystonia:
Patients with PD suffer from pain related to multiple 
pathogenic mechanisms, including central and periph-
erally mediated pain. Some of this may be related to 
immobilization from bradykinesia or dystonia. Exercise, 
physical therapy, pain management and botulinum 
toxin injections for dystonia may improve the quality of 
life of the patient.[28-30] 
When to Refer to a Neurologist
Primary care providers can diagnose and treat Parkinsons 
however consider referring to a neurologist if diagnosis is not 
clear; difficulty in managing or complications with manage-
ment; suboptimal response with management options
Importance of Multidisciplinary Care in the 
Management of Parkinson’s disease
Effective management of PD not only includes management 
of motor and non-motor symptoms but also addressing 
multiple areas of rehabilitation and improving the quality of 
life of the individual as a whole. There is a significant role 
for speech therapy, swallow evaluations, physical 
therapy, exercise and gait training from the time of 
diagnosis. Counseling patients and discussing possible 
modifications to their life style and home set-up in 
anticipation of expected disease progressionalsoare 
important. There is increasing data to suggest that 
exercise is neuroprotective for Parkinson’s disease, may 
improve executive function and slow progression of 
motor symptoms. SPARX trial and other smaller studies 
show that exercise improves motor scores in patients 
with Parkinson’s disease hence reducing falls and 
improves quality of life.[31-44]  Levodopa therapy is related 
to increase homocystine due to its metabolism by COMT 
enzyme. This theoretically increases the risk of stroke in 
patients suffering from Parkinson’s treated with 
levodopa. It might be reasonable to treat prophylacti-
cally with Vitamin B 12, folate, Vitamin B6.[45] Rehabili-
tation measures are focused towards improving mobility 
and preventing fall-related morbidity. The team caring for 
a PD patient should ideally be a combination of a physi-
cian, speech therapist, occupational therapist and 
physical therapist.[13, 46, 47]
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Deep Brain Stimulation in Parkinson’s disease [21] 
Deep brain stimulation of the sub thalamic nucleus or 
globus pallidus internum is used in the treatment of motor 
symptoms of PD. There are multiple theories to suggest 
the mechanism of action including a micro-lesioning 
effect, resetting of aberrant pathways and circuits and 
modulating excito-toxicity.
Deep brain stimulation of the subthalamic nucleus or globus 
pallidum may be considered in the following situations.
• Medication refractory disabling tremor.
• Carbidopa/Levodopa responsive disease.
• Motor fluctuations (on-off fluctuating motor symptoms
 that require high doses of medications that need to be
 given very frequently.
• Disabling dyskinesias.
• Patient does not have dementia or severe depression.
Axial and autonomic symptoms and freezing of the gait 
usually does not get better with this surgery. The surgery 
should only be done by high trained and experienced 
Parkinson’s disease surgeons and after the surgery the 
medications and the stimulator needs to be adjusted by 
experienced Parkinson’s disease neurologists. It requires 
life-long management by these teams and if not done and 
managed properly can often make the condition of the 
patient worse after the surgery.
Treatment of Non-Motor Symptoms in
Parkinson’s Disease
Non-motor symptoms are a major contributor to impaired 
quality of life of patients suffering from PD. [5] However, 
these symptoms are often neglected during evaluation 
and treatment. Non-motor symptoms are often easily 
treatable, but lack of attention to them may make treat-
ment of motor symptoms more difficult.[12] Non-motor 
symptoms include behavioral symptoms like depression, 
anxiety and psychosis, sleep disorders, dementia, dysau-
tonomia (dysphagia, drooling, constipation, urinary 
urgency and frequency, orthostatic hypotension) and 
sensory symptoms (pain, Restless Legs Syndrome, numb-
ness, joint stiffness in the limbs affected by the symp-
toms, etc). Non-motor symptoms can precede motor 
symptoms by years.
Sleep Disorders:
These include rapid eye movement (REM) sleep behavi or 
disorder (acting out dreams), insomnia, restless legs 
syndrome (RLS), and poor sleep maintenance. Usually 
the history provides the diagnostic clues needed to 
address sleep issues. Insomnia can be related to lack of 
dopamine or underlying anxiety/ depression. Nocturia 
may disturb the normal sleep pattern and may be due 
to an over active bladder or an underlying sub-clinical 
urinary tract infection.. Dopaminergic drug-wearing-off 
may contribute to poor sleep and this may require a 
bedtime dose of a long acting dopaminergic agent. 
Restless legs syndrome is commonly associated with 
Parkinson's disease and can be readily diagnosed and 
treated. RLS presents with restlessness, pain, cramps 
or vague discomfort in the legs upon rest, particularly 
after laying down to sleep at night. The symptoms 
improve upon movement, such as moving the legs or 
getting up and walking, but symptoms often return once 
the patient is recumbent again. RLS is associated with 
involuntary leg movements as well, which can occur 
during wakefulness or sleep. RLS symptoms should 
trigger a search for underlying iron deficiency, which 
should then be treated with iron replacement and 
Vitamin C which may facilitate its absorption. If iron 
deficiency is not present, RLS responds well to dopa-
minergic agonists such as ropinirole, typically adminis-
tered 2 hours before bedtime. Gabapentin, pregabalin 
and tramadol also are effective REM sleep behavior 
disorder includes a variety of presentations wherein 
patients may seem to be acting out dreams. Questioning 
the family members may reveal the patient has been 
talking in their sleep or even thrashing around and 
acting out physical fights while asleep (which may result 
in injuries). Always screen for REM sleep behavior disorder 
as it is a treatable condition.[22-25] It is usually responsive 
to a low dose of clonazepam.
Depression And Anxiety:
Mood disorders are common in Parkinson's disease and 
are frequently under-recognized and under-treated. PD 
patients with depression may be difficult to motivate to 
engage in regular exercise and in rehabilitation 
programs.  They also are more likely to be noncompliant 
with treatment. Serotonin specific reuptake inhibitors 
(SSRI's) often are effective in usual doses and can 
greatly improve the quality of life of the patients. 
Episodic shortness of breath and sweating are often 
seen with advancing Parkinson's disease and may or 
may not respond to dopaminergic medication. These 
resemble panic attacks.[17,18]. Anxiety can be a non-
motor component of PD and although it perhaps most 
often appears as a wearing off phenomenon, it also can 
present as a more pervasive sense of anxiety in some 
patients. It can often be treated by giving the dopaminergic 
medications more frequently at lower doses. 
Dementia:
PD dementia may develop in people after several years 
and correlates with the presence of subcortical and 
cortical Lewy bodies. Environmental modifications are 
the best tolerated interventions. Try to minimize 
changes to routine, provide familiar things and memory 
cues to minimize agitation. 
Discontinue potential aggravators: 
Anticholinergics, amantadine, tricyclic antidepressants, 
tolterodine and oxybutynin, benzodiazepines. If treatment 
becomes necessary, the addition of a cholinesterase 
inhibitor, such as rivastigmine, donepezil or galantamine 
may be considered. Memantine also may be tried.[26, 27]
Psychosis:
Symptoms of psychosis, such as hallucinations, 
delusions, and illusions, are complications of therapy 
and also may arise from the progression of the disease 
process. When they occur, it is important to first correct 
any metabolic abnormalities or fluid imbalance and to 
treat any infection. It is important to minimize poly-
pharmacy. Decreasing or stopping non-levodopa medi-
cations and optimizing levodopa can improve psychosis. 
Antipsychotics may be needed, but those that are 
potent dopamine depleting drugs can worsen Parkin-
sonism, especially the typical antipsychotics. Quetia-
pine is a sedating antipsychotic that does not appear to 
worsen the motor symptoms of Parkinson's disease.  
However as with other atypical antipsychotics, there 
may be a small risk of cardiac complications and therefore 
its use requires considering the risks and benefits for 
each individual patient.
 
Urinary Urgency, Frequency and Nocturia:
These are common autonomic symptoms in PD. Recog-
nizing and treating sub-clinical urinary tract infection is 
very important. Initial treatment may involve reduced 
intake of fluids after 6 pm and no caffeinated drinks 
after 12 noon. If that is not sufficient, then anticholiner-
gic medications may help. Anticholinergics that do not 
cross the blood brain barrier are better, since these do 
not worsen cognition. Tolterodine (2 mg twice daily) can 
be considered for these symptoms. Botulinum toxin 
type A injected in the detrusor muscle can also help but 
is a very expensive form of treatment that should be 
given only by trained physicians.[22,23]. For patients who 
cannot tolerate medications, diapers and bedside 
urinals should be available for patients.
Dysphagia:
Multiple factors contribute to dysphagia in PD. Optimization 
of motor control with dopamine replacement therapy 
may be helpful. Speech therapy is important along with 
assessment of swallowing and advice regarding the 
prevention of aspiration. Enteral feeding options 
(short-term nasogastric tube or percutaneous endo-
scopic gastrostomy) may be needed in advanced cases. 
[24]. Eating pureed and soft foods with the head slightly 
bent may be better and extra care with thin fluids like 
water and tough foods like meat that are more likely to 
cause dysphagia is important. Pills can be also be 
crushed and administered with yogurt to facilitate 
swallowing.
Orthostatic hypotension:
This is very important to recognize, prevent and treat as it 
can cause dizziness, fainting spells and falls. This is 
aggravated by volume depletion, diuretics, antihyperten-
sive drugs, tricyclic antidepressants, nitrates and alpha-
blockers used to treat prostatic hypertrophy. Dopaminer-
gic drugs also may induce orthostatic hypotension. It 
improves with increased salt intake.  Elevating the head-
end of the bed at night (30–40°) may be helpful, as may 
wearing of waist-high elastic-pressure stockings and/or 
abdominal binders (if weather allows). Changing positions 
slowly and exercises of the legs (leg crossing, toe raising, 
and thigh contraction) before sitting up and standing can 
help. If all of these are unsuccessful, medications, such 
as midodrine or fludrocortisone, may be necessary. [25,26]. 
Domperidone can block the peripheral effect of the dopa-
minergic medications and can help as well.
Constipation:
Constipation is a manifestation of general bradykinesia 
and autonomic dysfunction in Parkinson’s disease. This 
is a common problem aggravated by poor oral intake of 
water/fiber. Bowel dysfunction has two components 
decreased bowel movement frequency and difficulty 
with the act of defecation. Decreased bowel movement 
frequency results from slow colon transit and the 
difficulty with the act of defecation is due to impaired 
coordination and relaxation of the anorectal muscles.  
Slow transit constipation often responds to increasing 
water intake, fiber (ispaghula husk) and regular use of 
Milk of Magnesia or lactulose. Defecatory dysfunction 
usually does not respond to these interventions.
Drooling:
Drooling is another common and distressing symptom. 
Drooling is typically due to impairment of the swallowing 
mechanism rather than overproduction of saliva and 
may improve with chewing gum or sucking on honey or 
ice. Drooling may require use of anticholinergic agents 
or botulinum toxin injections into the salivary glands [19]. 
[48, 49]
Resources and Support for Patients with Parkinson’s disease
There are many global patient education and advocacy forums where patients may be referred for information and 
counseling. 
Pakistan Parkinson's Society 
American Parkinson’s Disease Association www.apdaparkinson.org  
National Parkinson Foundation. www.parkinson.org
The Michael J. Fox Foundation for Parkinson's Research www.michaeljfox.org
World Parkinson Congress.  www.pdf.org/world_parkinson_congress
Gait Training: Take larger steps and make larger truns
Home modifications; - Imporve lighting. - Remove rugs and minimize clutter. - Avoid slippery surfaces
Careful selection of gait aid: Usually walker better than cane
Most Falls occur during Freezing: Use Laser pointers or visual cues to help re-initiate gait
Always consider an early referral to Physical medicine
Work closely with the family and care takers
However anticholinergics should generally be avoided in 
the elderly patients and those with cognitive impairment 
as they can result in confusion, hallucinations, blurring 
of vision, constipation and urinary retention.
Pain and Dystonia:
Patients with PD suffer from pain related to multiple 
pathogenic mechanisms, including central and periph-
erally mediated pain. Some of this may be related to 
immobilization from bradykinesia or dystonia. Exercise, 
physical therapy, pain management and botulinum 
toxin injections for dystonia may improve the quality of 
life of the patient.[28-30] 
When to Refer to a Neurologist
Primary care providers can diagnose and treat Parkinsons 
however consider referring to a neurologist if diagnosis is not 
clear; difficulty in managing or complications with manage-
ment; suboptimal response with management options
Importance of Multidisciplinary Care in the 
Management of Parkinson’s disease
Effective management of PD not only includes management 
of motor and non-motor symptoms but also addressing 
multiple areas of rehabilitation and improving the quality of 
life of the individual as a whole. There is a significant role 
for speech therapy, swallow evaluations, physical 
therapy, exercise and gait training from the time of 
diagnosis. Counseling patients and discussing possible 
modifications to their life style and home set-up in 
anticipation of expected disease progressionalsoare 
important. There is increasing data to suggest that 
exercise is neuroprotective for Parkinson’s disease, may 
improve executive function and slow progression of 
motor symptoms. SPARX trial and other smaller studies 
show that exercise improves motor scores in patients 
with Parkinson’s disease hence reducing falls and 
improves quality of life.[31-44]  Levodopa therapy is related 
to increase homocystine due to its metabolism by COMT 
enzyme. This theoretically increases the risk of stroke in 
patients suffering from Parkinson’s treated with 
levodopa. It might be reasonable to treat prophylacti-
cally with Vitamin B 12, folate, Vitamin B6.[45] Rehabili-
tation measures are focused towards improving mobility 
and preventing fall-related morbidity. The team caring for 
a PD patient should ideally be a combination of a physi-
cian, speech therapist, occupational therapist and 
physical therapist.[13, 46, 47]
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Fall prevention in Parkinson’s Disease.
